Clinical Trial Update: Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. [Phase 3]

View source ↗

Summary

A phase 3 trial is evaluating adjuvant combination therapy with encorafenib and binimetinib for high-risk stage II melanoma with a BRAF mutation; the study is a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING